Charles S. Berkman
2021 - Ligand Pharmaceuticals
In 2021, Charles S. Berkman earned a total compensation of $3M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 53% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,257 |
|---|---|
| Option Awards | $649,308 |
| Salary | $451,682 |
| Stock Awards | $1,665,811 |
| Other | $10,890 |
| Total | $2,980,948 |
Berkman received $1.7M in stock awards, accounting for 56% of the total pay in 2021.
Berkman also received $203.3K in non-equity incentive plan, $649.3K in option awards, $451.7K in salary and $10.9K in other compensation.
Rankings
In 2021, Charles S. Berkman's compensation ranked 4,459th out of 12,406 executives tracked by ExecPay. In other words, Berkman earned more than 64.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,459 out of 12,406 | 64th |
Division Manufacturing | 1,833 out of 5,494 | 67th |
Major group Chemicals And Allied Products | 762 out of 2,369 | 68th |
Industry group Drugs | 679 out of 2,090 | 68th |
Industry Pharmaceutical Preparations | 484 out of 1,537 | 69th |
Source: SEC filing on April 22, 2022.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2021.